KW Wealth Management LLC Purchases Shares of 3,624 Johnson & Johnson $JNJ

KW Wealth Management LLC acquired a new position in Johnson & Johnson (NYSE:JNJ) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 3,624 shares of the company’s stock, valued at approximately $672,000. Johnson & Johnson accounts for approximately 1.1% of KW Wealth Management LLC’s investment portfolio, making the stock its 26th largest position.

Several other hedge funds have also recently added to or reduced their stakes in the business. Evolution Wealth Management Inc. acquired a new position in shares of Johnson & Johnson during the second quarter worth approximately $27,000. Clayton Financial Group LLC bought a new position in Johnson & Johnson during the third quarter worth $28,000. Semmax Financial Advisors Inc. increased its position in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares during the period. GFG Capital LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at $35,000. Finally, Signature Resources Capital Management LLC boosted its holdings in Johnson & Johnson by 262.9% in the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after purchasing an additional 184 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of research analyst reports. Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Guggenheim lifted their price objective on Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a report on Friday, December 5th. HSBC restated a “buy” rating and issued a $240.00 target price on shares of Johnson & Johnson in a research note on Wednesday, December 10th. Finally, Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target on the stock in a research note on Monday, October 20th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $211.25.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $206.93 on Wednesday. The business has a 50 day simple moving average of $200.25 and a 200 day simple moving average of $181.93. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a market capitalization of $498.56 billion, a PE ratio of 19.97, a price-to-earnings-growth ratio of 2.25 and a beta of 0.36. Johnson & Johnson has a one year low of $140.68 and a one year high of $215.18.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.